Skip to main content
Eli Lilly and Company logo

Eli Lilly and Company

4.0
LLY

A Eli Lilly and Company Company

www.lilly.com
Location
Indianapolis, Indiana
Size
10,001+ employees
Revenue
$10+ billion (USD)
Industry
Pharmaceutical Manufacturing
Founded
1876

Eli Lilly and Company: Nearly 150 Years of Transforming Science Into Healing

Eli Lilly and Company stands as a global pharmaceutical leader dedicated to turning science into life-changing medicines. Founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, this Fortune 500 organization has grown to employ over 10,000 professionals worldwide with annual revenues exceeding $10 billion. With a strong presence across major U.S. cities and international locations, Lilly continues its founder's vision: "Take what you find here and make it better and better."

Scientific Innovation Across Critical Health Areas

Harnessing the power of biotechnology, chemistry, and genetic medicine, Lilly's scientists urgently advance breakthrough discoveries in:

  • Diabetes care and metabolic disease
  • Oncology and cancer therapeutics
  • Immunology and inflammatory conditions
  • Neuroscience and neurological disorders

The company's commitment to scientific excellence drives innovation across research and development, clinical trials, regulatory affairs, manufacturing, and commercial operations.

Career Excellence and Professional Growth

  • 1,000+ active opportunities spanning research, clinical development, manufacturing, and corporate functions
  • Comprehensive training programs and professional development initiatives at all career levels
  • Competitive compensation with robust health benefits and retirement planning
  • Global career mobility across international operations and diverse therapeutic areas
  • Meaningful impact contributing to breakthrough medical discoveries that improve lives worldwide

Values Driven Culture

Lilly's corporate culture is built on three foundational values: excellence, integrity, and respect for people. These principles guide every aspect of the organization, creating an environment where employees thrive while advancing medical science. With a 4.0 Glassdoor rating, the company demonstrates its commitment to both scientific advancement and employee satisfaction.

Community Impact and Purpose

Beyond pharmaceutical innovation, Lilly's dedication to making life better extends to substantial community philanthropy and volunteer initiatives. Employees have opportunities to contribute meaningfully both professionally and personally, giving back to communities through service and support.

Mission

We make medicines that help people live longer, healthier, more active lives.

Frequently Asked Questions

Eli Lilly and Company employs over 10,000 professionals worldwide across its global operations, research facilities, and manufacturing centers.

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho...

Read Full Article

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines. In 2020, Lilly partnered with...

Read Full Article

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

Based on these trial results, Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes. At 48...

Read Full Article

Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain INDIANAPOLIS, Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain. The facility will...

Read Full Article

Lilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain INDIANAPOLIS, Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to build a new €2.6 billion (3 billion USD) manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain. The...

Read Full Article